Anxiety disorders affect an estimated 40 million adults in the United States, making them among the most prevalent mental health conditions in the country, yet fewer than 37% of those affected receive treatment (Anxiety and Depression Association of America, n.d.). For patients on the Main Line and throughout Delaware County who have not found adequate relief through first-line interventions, emerging neuromodulation technologies offer a scientifically grounded path forward. At Complete Mind Care in Villanova, we offer Deep TMS therapy using the BrainsWay H-Coil system — an FDA-cleared, non-invasive brain stimulation approach used for adults with depression and comorbid anxiety symptoms, also known as anxious depression (BrainsWay, 2021).
Understanding the Neural Architecture of Anxiety
Anxiety is not simply a state of mind; it is a pattern of dysregulation distributed across interconnected brain networks. Neuroimaging research has consistently identified hyperactivity in the amygdala, disrupted prefrontal cortical regulation, and altered connectivity within the default mode network as core features of anxiety disorders (Etkin & Wager, 2007). These neurobiological signatures explain why many patients continue to experience significant symptoms even after sustained trials of SSRIs, SNRIs, or benzodiazepines. The neurobiology of anxiety demands treatment approaches that directly target the circuits involved, not merely the neurotransmitter systems those circuits rely upon.
Deep TMS — short for Deep Transcranial Magnetic Stimulation — uses magnetic pulses to modulate neuronal activity in targeted brain regions. The BrainsWay H-Coil technology, which we use at our Villanova clinic, was specifically engineered to stimulate structures located deeper and more broadly than conventional figure-eight TMS coils allow (BrainsWay, 2022). This includes the medial prefrontal cortex and anterior cingulate regions that play central roles in emotional regulation and fear extinction. By delivering controlled, repetitive magnetic pulses to these areas, Deep TMS works to normalize the abnormal hyperactivity patterns associated with anxiety symptoms in appropriate patients.
What the Clinical Evidence Shows
Clinical evidence submitted for FDA review supports BrainsWay Deep TMS for reducing comorbid anxiety symptoms in adult patients with major depressive disorder who have not achieved satisfactory improvement from prior antidepressant medication treatment in the current episode (BrainsWay, 2021). Additional research on Deep TMS has examined stimulation of lateral and medial prefrontal targets in major depressive disorder, including patients with anxious depression features (Zangen et al., 2023). In 2021, the FDA cleared the BrainsWay Deep TMS system for reduction of comorbid anxiety symptoms in adults with depression — an important expansion that reflects growing evidence for this technology in anxious depression.
At Complete Mind Care, we recognize that results vary by individual and that no single intervention works equally for all patients. Our approach is to integrate Deep TMS within a comprehensive, individualized treatment plan that may also incorporate psychotherapy, medication optimization, or neurofeedback depending on each patient’s clinical profile.
What to Expect During Deep TMS Treatment
For Main Line residents considering Deep TMS, the treatment experience is straightforward and does not require sedation, recovery time, or hospitalization. During each session, which typically lasts approximately 20 minutes, patients sit comfortably while the BrainsWay H-Coil helmet is positioned over the head. The device delivers a series of brief magnetic pulses that some patients describe as a tapping or clicking sensation on the scalp. Most patients tolerate the treatment well, with mild scalp discomfort or headache being the most commonly reported side effects.
A standard course of Deep TMS for anxiety symptoms typically involves five sessions per week over a four- to six-week period. We schedule an initial consultation to review each patient’s treatment history, symptom burden, and clinical goals before beginning any protocol. This evaluation informs the specific coil placement, stimulation parameters, and session structure we use — an approach grounded in precision rather than protocol-by-default. To learn more about how TMS treatment is personalized for each patient, read our post on TMS for Anxiety: Personalizing Treatment Through Brain Mapping.
Addressing Common Barriers to Care
One of the most common obstacles we encounter among patients in the Villanova and broader Main Line community is uncertainty about whether Deep TMS is appropriate for their diagnosis. Many patients arrive having been told they have “generalized anxiety” or “panic disorder” but remain unsure whether their condition meets criteria for neuromodulation intervention. We encourage a direct consultation rather than self-assessment; our clinical team is experienced in evaluating complex presentations, including cases where anxiety co-occurs with depression, ADHD, or OCD.
A second barrier we frequently address is the concern about cost and insurance coverage. Deep TMS for anxiety-related indications has different coverage pathways than TMS for major depressive disorder. We work closely with each patient to navigate prior authorization, gather necessary documentation, and explore all available options. We believe that access to evidence-based, brain-based therapies should not be determined solely by insurance complexity.
Integration with Broader Treatment at Complete Mind Care
Deep TMS does not function in isolation. At our Villanova clinic, we view neuromodulation as one component within a broader architecture of care. Discuss with your provider whether combining Deep TMS with cognitive-behavioral therapy, acceptance-based approaches, or medication management may optimize your outcomes. Research supports TMS as an effective treatment option for adults with major depression who have not benefited adequately from antidepressant medication, and related studies have examined quality-of-life and functional outcomes in clinical practice (Carpenter et al., 2012; Janicak et al., 2013). Our collaborative team structure means that your psychiatrist, nurse practitioner, and therapist remain in communication throughout your treatment course, adjusting the plan as your clinical picture evolves.
The Main Line and Delaware County communities have access to a level of mental health expertise that many patients do not realize exists locally. Remission is our mission — not symptom management, not incremental improvement, but genuine, sustained relief that allows patients to re-engage with their lives, their families, and their work.
Frequently Asked Questions
What is Deep TMS and how is it different from regular TMS?
Deep TMS uses the BrainsWay H-Coil system, which generates magnetic fields that penetrate deeper into the brain than standard figure-eight coils used in conventional TMS. This allows stimulation of subcortical and medial brain structures that are particularly relevant to anxiety and depression. Both are non-invasive, non-medication approaches, but Deep TMS reaches a broader and deeper target area.
Is Deep TMS FDA-cleared for anxiety?
Deep TMS using the BrainsWay system received FDA clearance in 2021 for reducing comorbid anxiety symptoms in adult patients with depression, also known as anxious depression. This clearance specifically addresses anxiety symptoms that occur alongside major depressive disorder. We conduct a thorough clinical evaluation to determine whether a patient’s presentation aligns with this indication.
How many Deep TMS sessions will I need?
A standard course typically involves five sessions per week over four to six weeks, though treatment duration may vary depending on individual response and clinical complexity. Your provider will assess your progress throughout the course and may adjust the protocol accordingly. Many patients begin noticing symptom changes within two to three weeks of consistent treatment.
Can I continue my current medications during Deep TMS?
In most cases, patients continue their existing medication regimens during Deep TMS treatment. We complete a comprehensive medication review at the initial consultation to identify any contraindications and to assess whether medication adjustments may enhance treatment response. Discuss with your provider the specific approach that is safest and most effective for your situation.
Does Deep TMS for anxiety work if I have tried other treatments?
Deep TMS may be appropriate for patients who have had an inadequate response to medications or who prefer a non-pharmacological approach. Clinical evidence supporting the anxious depression indication includes patients who did not achieve satisfactory improvement from previous antidepressant medication treatment in the current episode (BrainsWay, 2021). Results vary by individual, and a thorough evaluation helps us determine whether Deep TMS is an appropriate next step.
Key Takeaways
Deep TMS using the BrainsWay H-Coil system stimulates deeper brain structures than conventional TMS, targeting regions central to anxiety regulation.
The BrainsWay system received FDA clearance for reducing comorbid anxiety symptoms in adults with depression in 2021, with growing evidence in anxious depression.
A standard Deep TMS course involves daily sessions over four to six weeks and does not require sedation or recovery time.
Complete Mind Care in Villanova combines Deep TMS with individualized psychotherapy, medication management, and neurofeedback within a comprehensive treatment plan.
Our clinical team works with patients to navigate insurance, prior authorization, and treatment planning to reduce barriers to access.
Medical Disclaimer: The information provided in this blog is for educational purposes only and does not constitute medical advice. Treatment outcomes vary by individual. Results may vary. Please consult with a qualified healthcare provider before beginning any new treatment. Discuss with your provider whether this treatment is appropriate for you.
Conclusion
Anxiety disorders are among the most under-treated conditions in the Philadelphia region, not because effective options are unavailable, but because patients and providers alike may not be aware of what modern brain-based therapies can offer. At Complete Mind Care, our Villanova clinic brings the depth of clinical experience — including a background building and operating 35 TMS clinics — to every patient we evaluate. If you or someone you care about on the Main Line is living with anxiety that has not fully responded to standard treatments, we invite you to schedule a consultation with our team. Our Villanova location is at 795 E Lancaster Ave, Suite 210, Villanova, PA 19085, or you may reach us by phone at 215-918-7939. Remission is our mission — and we are ready to work toward that goal with you.
References
Anxiety and Depression Association of America. (n.d.). Facts and statistics. https://adaa.org/understanding-anxiety/facts-statistics
BrainsWay. (2021, August 18). FDA clears BrainsWay Deep TMS™ system for decreasing anxiety symptoms in depressed patients. https://www.brainsway.com/news_events/fda-clears-brainsway-deep-tms-system-for-decreasing-anxiety-symptoms-in-depressed-patients/
BrainsWay. (2022, August 29). BrainsWay receives new FDA clearance for treating depression and anxious depression. https://www.brainsway.com/news_events/brainsway-receives-new-fda-clearance-for-treating-depression-and-anxious-depression/
Carpenter, L. L., Janicak, P. G., Aaronson, S. T., Boyadjis, T., Brock, D. G., Cook, I. A., Dunner, D. L., Lanocha, K., Solvason, H. B., & Demitrack, M. A. (2012). Transcranial magnetic stimulation (TMS) for major depression: A multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depression and Anxiety, 29(7), 587–596. https://doi.org/10.1002/da.21969
Etkin, A., & Wager, T. D. (2007). Functional neuroimaging of anxiety: A meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. American Journal of Psychiatry, 164(10), 1476–1488. https://doi.org/10.1176/appi.ajp.2007.07030504
Janicak, P. G., Dunner, D. L., Aaronson, S. T., Carpenter, L. L., Boyadjis, T., Brock, D. G., Cook, I. A., Lanocha, K., Solvason, H. B., Bonneh-Barkay, D., & Demitrack, M. A. (2013). Transcranial magnetic stimulation for major depression: A multisite, naturalistic, observational study of quality of life outcome measures in clinical practice. CNS Spectrums, 18(6), 322–332. https://doi.org/10.1017/S1092852913000357
Zangen, A., Harmelech, T., Tendler, A., Roth, Y., Pell, G. S., Popovtzer, A., Nechaev, V., & Zibman, S. (2023). Pursuing personalized medicine for depression by targeting the lateral or medial prefrontal cortex with Deep TMS. JCI Insight, 8(4), e165271. https://doi.org/10.1172/jci.insight.165271